U.S. Software Stock News

MGP Ingredients, Inc.'s ( NASDAQ:MGPI ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a buy right now...

Key Insights Significant control over CSP by individual investors implies that the general public has more power to...

Key Insights Significant insider control over iHuman implies vested interests in company growth Yufeng Chi owns 56% of...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...

Kellanova (K) has quietly delivered steady gains over the past year, with the stock up about 6% and roughly 4% in the past 3 months, outpacing many packaged food peers. See our latest analysis for Kellanova. That steady climb reflects a market that is gradually rewarding Kellanova for consistent execution, with a 90 day share price return of just over 4% and a five year total shareholder return nearing 70%. This may hint that momentum is still quietly building. If Kellanova’s slow and steady...

If you are wondering whether New Fortress Energy is a bargain after its big sell off, you are not alone. This stock now sits in territory where price and value may be telling very different stories. In the very short term the shares have bounced, up 28.7% over the last week and 5.4% over the last month, but that comes after a brutal slide of 90.4% year to date and 87.3% over the past year. Those moves have unfolded against a backdrop of ongoing execution on its liquefied natural gas...

Dakota Gold (DC) is back on radar after fresh assay results from its Richmond Hill Oxide Heap Leach project confirmed high grade gold hits and step out drilling that pushes resource boundaries outward. See our latest analysis for Dakota Gold. The latest drill success comes on top of Dakota Gold’s recent conference appearances in London, and the market seems to be taking notice, with a year to date share price return of around 133 percent and a 1 year total shareholder return above 140...

If you have been wondering whether John Wiley & Sons at around $32 is a bargain or a value trap, you are not alone and this article is going to tackle that question head on. Despite being a long established name in publishing and research, the stock has had a rough ride lately, falling about 10.9% over the last week, 15.2% over the last month and roughly 24.9% year to date, which naturally raises questions about whether the market has become too pessimistic. Some of this share price weakness...

If you are wondering whether Avadel Pharmaceuticals at around $21 a share still has room to run or is already priced for perfection, you are not alone. This breakdown is designed to give you a clear, valuation focused view. The stock has dipped about 0.7% over the last week, but it is still up 12.6% over the past month and 94.0% year to date, with a 113.4% gain over the last year shifting how the market thinks about its risk and reward profile. Much of that surge has been driven by growing...

Wondering if Avidity Biosciences is still a smart buy after its huge run, or if most of the upside is already priced in? Here is a look at what the numbers suggest about value from here. The stock has cooled slightly in the last week, slipping about 0.1%, but it is still up 2.6% over the past month, 129.7% year to date, and 556.6% over 3 years, which indicates the market has rapidly rewritten its expectations. That surge in optimism has been driven largely by excitement around Avidity's...

Hyster-Yale recently reported its latest quarterly results and declared a dividend, underscoring its ongoing role manufacturing and servicing lift trucks and components worldwide. The company’s emphasis on aftermarket services and operational performance highlights how it is trying to deepen recurring revenue streams within the industrial equipment sector. Next, we’ll examine how the quarterly earnings and dividend announcement interact with Hyster-Yale’s margin-improvement investment...

If you are wondering whether Fidelis Insurance Holdings is a sleeper value play or a stock to avoid, you are in the right place. We are going to unpack what the current price is really telling us about the business. Despite a modest 0.6% gain year to date and a near flat 30 day move of 0.1%, the stock is still down 7.9% over the past year after a recent 5.0% pullback over the last week, which can leave investors unsure whether this is a buying opportunity or a warning sign. Recent news...

Absci Corporation recently dosed the first healthy volunteers in its Phase 1/2a HEADLINE trial of ABS-201, an AI-designed anti-prolactin receptor antibody for androgenetic alopecia, with interim data planned for the second half of 2026. The company also aims to leverage safety and pharmacokinetic insights from this study to accelerate development of ABS-201 for endometriosis, potentially broadening the drug’s addressable patient population. Against this backdrop, we’ll examine how the...

Black Diamond Therapeutics recently reported topline Phase 2 data for silevertinib in first-line non-small cell lung cancer patients with non-classical EGFR mutations, and outlined plans to start a randomized Phase 2 trial in newly diagnosed glioblastoma in 2026. The early results, including strong central nervous system response rates and a broad range of EGFR alterations targeted, underscore silevertinib’s potential as a brain-penetrant precision therapy across multiple tumor types. We’ll...

It hasn't been the best quarter for Hess Midstream LP ( NYSE:HESM ) shareholders, since the share price has fallen 16...

As the U.S. stock market experiences a modest uptick following key inflation data, major indices like the Dow Jones and S&P 500 are nearing all-time highs, reflecting investor optimism despite recent economic uncertainties. In this environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets amid fluctuating market conditions.

U.S. stock indexes have recently ticked higher following key inflation data, suggesting cautious optimism among investors as they anticipate upcoming Federal Reserve policy decisions. In the context of this market environment, penny stocks remain a notable area for investors seeking potential growth opportunities outside of traditional blue-chip companies. Though the term "penny stocks" may seem outdated, these smaller or newer companies can still offer significant value and growth potential...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

This article explores whether MNTN is a beaten-down bargain or a value trap at current levels, and what the market might be overlooking. After sliding 48.8% year to date and another 9.2% over the last month, the stock has only managed a modest 0.7% uptick in the past week. This mix hints at both lingering caution and potential rebound interest. Recent headlines have focused on MNTN’s positioning in the evolving media and ad tech landscape, including its push to differentiate in a crowded...

When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying...

With a price-to-earnings (or "P/E") ratio of 42x Zurn Elkay Water Solutions Corporation ( NYSE:ZWS ) may be sending...

Some Keysight Technologies, Inc. ( NYSE:KEYS ) shareholders may be a little concerned to see that the Non-Executive...

PulteGroup, Inc. ( NYSE:PHM ) has announced that it will be increasing its dividend from last year's comparable payment...

Those following along with Fiserv, Inc. ( NASDAQ:FISV ) will no doubt be intrigued by the recent purchase of shares by...